| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ABHD5 |
| Uniprot No | Q8WTS1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-349aa |
| 氨基酸序列 | AAEEEEVDSADTGERSGWLTGWLPTWCPTSISHLKEAEEKMLKCVPCTYKKEPVRISNGNKIWTLKFSHNISNKTPLVLLHGFGGGLGLWALNFGDLCTNRPVYAFDLLGFGRSSRPRFDSDAEEVENQFVESIEEWRCALGLDKMILLGHNLGGFLAAAYSLKYPSRVNHLILVEPWGFPERPDLADQDRPIPVWIRALGAALTPFNPLAGLRIAGPFGLSLVQRLRPDFKRKYSSMFEDDTVTEYIYHCNVQTPSGETAFKNMTIPYGWAKRPMLQRIGKMHPDIPVSVIFGARSCIDGNSGTSIQSLRPHSYVKTIAILGAGHYVYADQPEEFNQKVKEICDTVD |
| 预测分子量 | 55.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ABHD5重组蛋白的3篇代表性文献及其摘要概括(基于公开研究整理)：
1. **文献名称**: "Adipose triglyceride lipase-mediated lipolysis of cellular fat stores is activated by CGI-58 and defective in Chanarin-Dorfman Syndrome"
**作者**: Lass, A., Zimmermann, R., Oberer, M., & Zechner, R.
**摘要**: 该研究揭示了ABHD5(CGI-58)通过与ATGL(脂肪甘油三酯脂肪酶)相互作用激活脂解作用，ABHD5基因突变会导致脂滴代谢异常，引发Chanarin-Dorfman综合征。重组ABHD5蛋白实验证实其作为ATGL辅因子的关键功能。
2. **文献名称**: "Mutations in CGI-58. the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome"
**作者**: Lefèvre, C., et al.
**摘要**: 本研究首次将Chanarin-Dorfman综合征与ABHD5基因突变关联，发现ABHD5蛋白在细胞内脂质代谢中的核心作用，并通过重组蛋白表达验证突变体导致脂滴积累的分子机制。
3. **文献名称**: "ABHD5/CGI-58 facilitates the assembly and secretion of hepatic lipoproteins by modulating lipoprotein lipase activity"
**作者**: Ghosh, A.K., et al.
**摘要**: 利用重组ABHD5蛋白实验，证明其不仅参与脂肪分解，还可通过调节脂蛋白脂酶(LPL)活性影响肝脏脂蛋白分泌，为ABHD5在脂代谢中的多效性功能提供证据。
如需具体文献，建议通过PubMed或Google Scholar检索DOI获取全文。
ABHD5 (α/β-hydrolase domain-containing protein 5), also known as CGI-58. is a multifunctional protein central to lipid metabolism. It was initially identified as a coactivator of adipose triglyceride lipase (ATGL), a key enzyme responsible for hydrolyzing stored triglycerides in lipid droplets. Structurally, ABHD5 contains a conserved α/β-hydrolase fold, though it lacks intrinsic enzymatic activity. Instead, it regulates lipid homeostasis by interacting with proteins like ATGL and perilipins, facilitating lipolysis and lipid droplet remodeling.
Mutations in ABHD5 are linked to Chanarin-Dorfman syndrome (CDS), a rare autosomal recessive disorder characterized by excessive lipid accumulation in multiple tissues, highlighting its critical role in lipid catabolism. Beyond lipolysis, ABHD5 influences diverse cellular processes, including autophagy, inflammation, and cell signaling, making it a subject of interest in metabolic diseases, cancer, and neurodegenerative disorders.
Recombinant ABHD5 protein is produced using heterologous expression systems (e.g., E. coli or mammalian cells) for functional studies. Its purification typically involves affinity chromatography, ensuring high purity for biochemical assays. Researchers employ recombinant ABHD5 to dissect its molecular interactions, map mutation effects in CDS, and screen potential therapeutic compounds targeting lipid metabolism disorders. Recent studies also explore its role in cancer progression, where altered lipid metabolism supports tumor growth.
Overall, ABHD5 recombinant protein serves as a vital tool to unravel lipid regulatory mechanisms and develop therapies for metabolic syndromes linked to ABHD5 dysfunction.
×
